|
|
PROGRAM - TUESDAY, MAY 19, 2009 |
| 7:15AM-8:15 AM |
|
|
EDUCATIONAL SYMPOSIUM - Sponsored by Medaxial |
| |
|
Once Upon a Time in Health Economics… Narrative vs. Analysis in Communicating Product Value
Symposium Description
|
| 7:15AM-8:15AM |
|
ISPOR SMALL GROUP MEETINGS/INVITATIONAL MEETINGS |
| |
|
|
| 8:00AM-8:30AM |
|
EXHIBITS & POSTER PRESENTATIONS VIEWING – SESSION II |
| |
|
|
| 8:30AM-9:30AM |
|
RESEARCH PODIUM PRESENTATIONS – SESSION III (6 concurrent session) |
| 8:30AM-9:30AM |
|
COMPLIANCE STUDIES |
| |
|
|
| |
|
| CM2: UTILIZATION AND PERSISTENCE OF ALISKIREN IN A REAL-WORLD ENVIRONMENT |
| Zeng F1, Lau H2, Hanson K2, Patel BV1, Gao S1 |
| 1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA |
|
| |
|
|
| |
|
| CM4: NONADHERENCE TO CLINICAL PRACTICE GUIDELINES FOR MULTIPLE DISEASE CONDITIONS IN A CALIFORNIA MEDICAID POPULATION |
| Nichol MB1, Knight TK1, Priest JL2, Wu J1, Cantrell CR2 |
| 1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA |
|
| 8:30AM-9:30AM |
|
DIABETES - OUTCOMES RESEARCH & HEALTH CARE POLICY STUDIES |
| |
|
| DB1: PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES |
| Aagren M1, Thomsen TL2, Knudsen VK3 |
| 1Novo Nordisk Inc, Princeton, NJ, USA, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk A/S, Bagsvaerd, Denmark |
|
| |
|
| DB2: ANTI-HYPERTENSIVE DRUG USE AND RISK OF DEMENTIA IN PATIENTS WITH DIABETES MELLITUS (DM) |
| Johnson ML1, Parikh NM2, Kunik M3, Schulz P4, Chen H1, Aparasu R1, Yadav R1, Morgan R5 |
| 1University of Houston, Houston, TX, USA, 2Analysis Group Inc, Boston, MA, USA, 3Center of Quality of Care and Utilization Studies, Veterans Affairs Medical Center, Houston, TX, USA, 4Baylor Neurology, Houston, TX, USA, 5University of Texas, Houston, TX, USA |
|
| |
|
| DB3: DIRECT AND INDIRECT COSTS ASSOCIATED WITH DIABETES PATIENTS WITH AND WITHOUT MACROVASCULAR COMORBIDITIES IN THE UNITED STATES |
| Qiu Y1, Fu AZ2, Radican L1 |
| 1Merck & Co., Inc, Whitehouse Station, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA |
|
| |
|
|
| 8:30AM-9:30AM |
|
HEALTH TECHNOLOGY ASSESSMENT |
| |
|
|
| |
|
| HT2: HEALTH TECHNOLOGY ASSESSMENT - A COMPREHENSIVE FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN ONTARIO |
| Johnson A1, Sikich N2, Evans G1, Evans W3, Giacomini M4, Glendining M5, Krahn MD6, Levin L7, Oh PI8, Perera C2 |
| 1Queen's University, Kingston, ON, Canada, 2Ministry of Health and Long Term Care, Toronto, ON, Canada, 3Juravinski Cancer Centre, Hamilton, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5Hamilton Health Sciences, Hamilton, ON, Canada, 6University Health Network, Toronto, ON, Canada, 7Ontario Ministry of Health and LongTerm Care, Toronto, ON, Canada, 8Toronto Rehabilitation Institute, North York, ON, Canada |
|
| |
|
|
| |
|
| HT4: IN PROMETHEUS' SHADOW: EPIDEMIOLOGICAL AND ETHICAL PERSPECTIVES ON OUTCOMES OF CARDIOPULMONARY RESUSCITATION |
| Levy A1, Koning F2, Lockey R2, Bellack N3, Christie T4, Desjardins E2 |
| 1University of British Columbia, Vancouver, BC, Canada, 2Providence Health Care, Vancouver, BC, Canada, 3University of Ottawa, Vancouver, BC, Canada, 4Atlantic Health Sciences Corporation, Saint John Regional Hospital, St John, NB, Canada |
|
| 8:30AM-9:30AM |
|
MEDICARE STUDIES I |
| |
|
|
| |
|
| MD2: RACIAL DISPARITIES IN ANTI-DEMENTIA MEDICATION, ANTI-DEPRESSANT, AND ANTIPSYCHOTIC USE AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS |
| Lin PJ1, Biddle AK2, Maciejewski ML3 |
| 1University of Maryland, Baltimore, MD, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Center for Health Services Research in Primary Care, Durham, NC, USA |
|
| |
|
| MD3: EFFECT OF LIPID LOWERING DRUG USE ON HOSPITALIZATIONS, EMERGENCY ROOM VISITS, AND MORTALITY IN MEDICARE DIABETIC POPULATION |
| Thumula V, Yang Y, Pace PF, Banahan BF, Wilkin NE, Lobb WB |
| University of Mississippi, University, MS, USA |
|
| |
|
|
| 8:30AM-9:30AM |
|
MODELING STUDIES |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| 8:30AM-9:30AM |
|
NEUROLOGICAL DISORDERS - OUTCOMES RESEARCH & HEALTH CARE POLICY STUDIES |
| |
|
| ND1: COST-EFFECTIVENESS OF DISEASE-MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: A POPULATION-BASED EVALUATION |
| Noyes K1, Bajorska A1, Chappel AR2, Schwid S1, Mehta LR2, Holloway R1, Dick A3 |
| 1University of Rochester School of Medicine, Rochester, NY, USA, 2University of Rochester, Rochester, NY, USA, 3The RAND Corporation, Pittsburgh, PA, USA |
|
| |
|
| ND2: DIRECT HEALTHCARE AND WORKLOSS BURDEN OF CHEMOTHERAPY-ASSOCIATED PERIPHERAL NEUROPATHY IN BREAST, OVARIAN, HEAD AND NECK, AND NON-SMALL CELL LUNG CANCER |
| Pike C1, Birnbaum HG1, Kaufman R1, Muehlenbein CE2, Pohl G2, Natale R3 |
| 1Analysis Group, Inc, Boston, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA |
|
| |
|
| ND3: PRESCRIBING PATTERNS AMONG DEMENTIA PATIENTS AT THE VETERANS AFFAIRS MARYLAND HEALTH CARE SYSTEM (VAMHCS) |
| Rattinger GB1, DeLisle S2, Onukwugha E1, Mullins CD1 |
| 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA |
|
| |
|
| ND4: COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA |
| Caloyeras JP1, Harrow B1, Wang C2, Beckmann K3, Knappertz V2, Pohl C3, Miller JD1, Russell MW1, Sandbrink R3, Gondek K2 |
| 1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Bayer Healthcare Pharmaceuticals Inc, Montville, NJ, USA, 3Bayer Schering Pharma AG, Berlin, P300, Germany |
|
| 9:45AM-10:45AM |
|
RESEARCH PODIUM PRESENTATIONS – SESSION IV (6 concurrent session) |
| 9:45AM-10:45AM |
|
HEALTH CARE MANAGEMENT STUDIES |
| |
|
| HM1: EFFICIENCY AND ECONOMIC BENEFITS ASSOCIATED WITH THE USE OF A PAYER-BASED ELECTRONIC HEALTH RECORD IN AN EMERGENCY DEPARTMENT AMONG A HEALTH INSURED POPULATION |
| Daniel GW1, Ewen E2, Willey VJ3, Shirazi M4, Malone DC5 |
| 1HealthCore, Wilmington, DE, USA, 2Christiana Care Health System, Newark, DE, USA, 3University of the Sciences in Philadelphia, Philadelphia, PA, USA, 4University of Arizona College of Medicine, Tucson, AZ, USA, 5University of Arizona College of Pharmacy, Tucson, AZ, USA |
|
| |
|
|
| |
|
|
| |
|
| HM4: THE IMPACT OF A PHARMACIST-PROVIDED TELEPHONE MEDICATION THERAPY MANAGEMENT PROGRAM ON MEDICATION AND HEALTH-RELATED PROBLEMS, MEDICATION ADHERENCE, AND TOTAL DRUG COSTS AMONG MEDICARE BENEFICIARIES: A 6-MONTH FOLLOW-UP |
| Moczygemba LR1, Barner JC2, Lawson KA2, Brown CM2, Gabrillo E3, Godley PJ4, Johnsrud M2 |
| 1Virginia Commonwealth University, Richmond, VA, USA, 2University of Texas at Austin, Austin, TX, USA, 3Scott and White Health Plan, Temple, TX, USA, 4Scott and White Health System, Temple, TX, USA |
|
| 9:45AM-10:45AM |
|
MEDICARE STUDIES II |
| |
|
| MD5: PREDICTORS OF ENROLLMENT IN MEDICARE PART D: ARE BENEFICIARIES RATIONAL? |
| Lines LM1, Menzin J1, Lang K1, Korn JR1, Neumann PJ2 |
| 1Boston Health Economics, Inc, Waltham, MA, USA, 2Tufts Medical Center, Boston, MA, USA |
|
| |
|
|
| |
|
| MD7: DOES MEDICARE HAVE AN IMPLICIT COST-EFFECTIVENESS THRESHOLD? |
| Chambers J1, Neumann PJ2, Buxton MJ3 |
| 1Mapi Values, Boston, MA, USA, 2Tufts Medical Center, Boston, MA, USA, 3Brunel University, Uxbridge, Middlesex, UK |
|
| |
|
| MD8: OUT OF POCKET PSYCHOTROPIC PRESCRIPTION BURDEN ON ELDERLY MEDICARE BENEFICIARIES BEFORE AND AFTER THE IMPLEMENTATION OF MEDICARE PART D |
| Chen H1, Chaudhari S2, Aparasu R1, Johnson M1 |
| 1University of Houston, Houston, TX, USA, 2Xcenda, Palm Harbor, FL, USA |
|
| 9:45AM-10:45AM |
|
MUSCULAR-SKELETAL DISORDERS - OUTCOMES RESEARCH |
| |
|
| MS1: ASSESSMENT OF PREFERENCE AND SATISFACTION WITH A WEEKLY ORAL TABLET VERSUS A 6-MONTH SUBCUTANEOUS INJECTION FOR THE TREATMENT OF OSTEOPOROSIS |
| Kendler DL1, Gold DT2, Horne R3, Borenstein J4, Varon SF4, Man HS4, Siddhanti S4, Satram-Hoang S4, Macarios D4, Bone HG5 |
| 1Clinical Research Centre, Vancouver, BC, Canada, 2Duke University Center for the Study of Aging and Human Development, Durham, NC, USA, 3The School of Pharmacy, University of London, London, UK, 4Amgen Inc, Thousand Oaks, CA, USA, 5Michigan Bone and Mineral Clinic, Detroit, MI, USA |
|
| |
|
| MS2: COMBINING THE SF-36 PHYSICAL FUNCTION SCALE AND THE HEALTH ASSESSMENT QUESTIONNAIRE TO IMPROVE MEASUREMENT OF PHYSICAL FUNCTION RHEUMATOID ARTHRITIS (RA): RESULTS: FROM THE PREMIER STUDY |
| Hammond G1, Yarlas A1, Kosinski M1, Roy S2, Cifaldi M2 |
| 1QualityMetric Incorporated, Lincoln, RI, USA, 2Abbott Laboratories, Abbott Park, IL, USA |
|
| |
|
| MS3: THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| Tang B1, McKenzie RS1, Freedman D2, Wagner S2, Piech CT1 |
| 1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Consumer Health Sciences International, Princeton, NJ, USA |
|
| |
|
| MS4: SOCIETAL COST OF RHEUMATOID ARTHRITIS (RA) IN THE UNITED STATES: METHODOLOGY FOR INCORPORATING INTANGIBLE COSTS |
| Birnbaum H1, Pike C1, Kaufman R1, Marynchenko M2, Kidolezi Y1, Cifaldi M3 |
| 1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, Montreal, QC, Canada, 3Abbott Laboratories, Abbott Park, IL, USA |
|
| 9:45AM-10:45AM |
|
QUALITY OF LIFE & UTILITY STUDIES |
| |
|
|
| |
|
| QL2: DEVELOPMENT OF AN ITEM BANK FOR A COMPUTER ADAPTIVE MEASURE OF FUNCTIONAL COGNITION FOR STROKE |
| Velozo CA1, Duncan P2, Wang JH3, Donovan NJ4, Heaton SC3, Kendall DL5, Kwon S6, Singletary FF7, Seago R8, Garretson KN9, Agonis JK7 |
| 1University of Florida/Department of Veterans Affairs, Gainesville, FL, USA, 2Duke University, Durham, NC, USA, 3University of Florida, Gainesville, FL, USA, 4Louisiana State University, Baton Rouge, LA, USA, 5University of Washington, Seattle, WA, USA, 6South Carolina College of Pharmacy - MUSC Campus, Charleston, SC, USA, 7Brooks Center for Rehabilitation Studies, Jacksonville, FL, USA, 8CNS Healthcare, Jacksonville, FL, USA, 9Brooks Rehabilitation Hospital, Jacksonville, FL, USA |
|
| |
|
| QL3: ESTIMATION OF UTILITY VALUES FOR DIABETES-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA |
| O'Reilly D1, Xie F1, Pullenayegum E1, Gerstein H2, Blackhouse G1, Tarride JE1, Goeree RA1 |
| 1McMaster University, Hamilton, ON, Canada, 2McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada |
|
| |
|
| QL4: VALIDATION OF THE TREATMENT RELATED IMPACT MEASURE FOR DIABETES TREATMENT AND DEVICE; TRIM-DIABETES AND TRIM-DIABETES DEVICE |
| Brod M1, Hammer M2, Christensen T2, Bushnell D3 |
| 1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Health Research Associates, Inc, Mountlake Terrace, WA, USA |
|
| 9:45AM-10:45AM |
|
RISK ASSESSMENT STUDIES |
| |
|
| RA1: CAN THE PUBLIC'S RISK PREFERENCE WHEN WEIGHING A DRUG'S RISK/BENEFIT BE TRUSTED? |
| Wilson L, Pelletier D, Motter C, Basu R, Owen M, Kuan RK, Cheng Y |
| University of California, San Francisco, San Francisco, CA, USA |
|
| |
|
|
| |
|
|
| |
|
| RA4: METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST GENERATION ADOLESCENTS (12-17) IN THE UNITED STATES |
| Hufstader MA1, Sias S1, Vaidya V2, White-Means S1 |
| 1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, Memphis, TN, USA |
|
| 9:45AM-10:45AM |
|
RESPIRATORY-RELATED DISORDERS - OUTCOMES RESEARCH & HEALTH CARE POLICY STUDIES |
| |
|
| RR1: QUARTERLY ASSESSMENT OF SHORT ACTING ß-AGONIST USE AS A PREDICTOR OF SUBSEQUENT HEALTH CARE SERVICES USE FOR ASTHMATICS IN THE U.S. |
| Blanchette CM1, Silver H1, Petersen H1, Kamble S2, Meddis D3, Gutierrez B3 |
| 1Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2The University of North Carolina at Charlotte, Charlotte, NC, USA, 3AstraZeneca, Wilmington, DE, USA |
|
| |
|
|
| |
|
| RR3: USE OF HEALTH CARE SERVICES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH BUDESONIDE/FORMOTEROL VIA DRY POWDER INHALER (BUD/FM DPI) VERSUS TIOTROPIUM DPI |
| Blais L1, Forget A2, Ramachandran S3 |
| 1Université de Montréal, Montreal, QC, Canada, 2Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 3AstraZeneca LP, Wilmington, DE, USA |
|
| |
|
| RR4: OUTCOMES ASSOCIATED WITH TIOTROPIUM USE IN COPD PATIENTS |
| Lee TA1, Wilke CT2, Joo M3, Stroupe KT4, Krishnan JA5, Schumock GT2, Pickard AS2 |
| 1Hines VA Hospital and Northwestern University, Chicago, IL, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Hines VA Hospital and University of Illinois at Chicago, Chicago, IL, USA, 4Midwest Center for Health Services & Policy Research, Hines, IL, USA, 5University of Chicago, Chicago, IL, USA |
|
| 10:45AM-11:00AM |
|
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II |
| |
|
|
| 11:00AM-11:15AM |
|
INCOMING PRESIDENTIAL ADDRESS |
| |
|
 Michael Barry PhD, MD
Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital and Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland |
| |
| 11:15AM-12:45PM |
|
SECOND PLENARY SESSION |
| |
|
A ROADMAP FOR KNOWING WHAT WORKS IN HEALTH CARE: WILL A US NATIONAL CLINICAL EFFECTIVENESS CENTER OR THE ARRA’s COMPARATIVE EFFECTIVENESS RESEARCH PROGRAM SHOW THE WAY?
The United States Institute of Medicine (IOM) in a recent report recommended to the US Congress to establish a single national clinical effectiveness assessment entity (program) with sufficient resource, authority, and capacity to facilitate the development of standards and processes that yield credible, unbiased, and understandable syntheses of available evidence on clinical effectiveness. For further information on this report, see: http://www.iom.edu/CMS/3809/34261/50718.aspx. More recently the IOM was asked by the US Congress, in the American Recovery and Reinvestment Act of 2009 (ARRA), to recommend priorities for spending the $1.1 billion on comparative effectiveness research. During this plenary session, a national clinical effectiveness entity and setting priorities for ARRA comparative effectiveness research will be discussed and debated.
11:15 – 11:25 AM |
 |
Moderator: John Hornberger MD, MS, Principal, CEDAR Associates LLC and Adjunct Clinical Professor of Medicine, Stanford University School of Medicine, Menlo Park, CA, USA |
11:25 – 11:45 AM |
Comparative Effectiveness Research or A Clinical Effectiveness Research Center: Showing the Way to Better Health Care |
| |
 |
Speaker: Hal Sox MD, MACP, Editor, Annals of Internal Medicine, American College of Physicians, Philadelphia, PA, USA |
11:45 – 12:05 PM |
Comparative Effectiveness Research to Practice Guidelines: The Challenges |
| |
 |
Speaker: Steve Shak MD, Chief Medical Officer, Genomic Health Inc., Redwood City, CA USA |
12:05 – 12:25 PM |
Comparative Effectiveness Research & “Fixing” the US Health Care System: A Reality Check |
| |
 |
Speaker: Alan Rosenberg MD, Vice President, Medical Policy, Technology Assessment & Credentialing Programs, WellPoint, Inc., Chicago, IL, USA |
12:25 – 12:45 PM |
Panel Discussion |
|
| |
| 12:45PM-1:15PM |
|
ISPOR AWARDS PRESENTATION |
| |
|
|
| 1:15PM-2:45PM |
|
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II |
| |
|
|
| 1:30PM-2:30PM |
|
EDUCATIONAL SYMPOSIUM - Sponsored by Archimedes |
|
|
Healthcare Modeling: Simulation Modeling in Intervention Prioritization
Symposium Description
|
| 2:45PM-3:45PM |
|
ISSUE PANELS – SESSION II (5 concurrent session) |
| |
|
CLINICAL OUTCOMES RESEARCH ISSUES |
| 2:45PM-3:45PM |
IP6: HETEROGENEITY AMONG HOMO SAPIENS: IMPLICATIONS FOR CLINICAL DEVELOPMENT, CLINICAL PRACTICE, AND PRICING AND REIMBURSEMENT
Moderator: William Crown PhD, President, i3 Innovus, Waltham, MA, USA
Panelists: Marc L. Berger MD, Vice President, Eli Lilly, Global Health Outcomes, Indianapolis, IN, USA; Victor M. Montori MD, Associate Professor, Mayo Clinic, Rochester, MN, USA; Ernst Berndt PhD, Professor, Massachusetts Institute of Technology, Sloan School, Cambridge, MA, USA |
| |
ECONOMIC OUTCOMES RESEARCH ISSUES |
| 2:45PM-3:45PM |
IP7: USE OF THE QALY FOR ECONOMIC EVALUATION: PRAGMATIC CHOICE OR UNJUSTIFIED EVIL?
Moderator: Louis Garrison PhD, Professor and Associate Director, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Panelists: Michael F. Drummond DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President, Health Economics, United BioSource Corporation, Health Care Analytics, Lexington, MA, USA |
| |
PATIENT-REPORTED OUTCOMES RESEARCH ISSUES |
| 2:45PM-3:45PM |
IP8: IMPLEMENTING FDA PRO GUIDELINES -- CONTENT VALIDITY AND GOOD MEASUREMENT PRACTICES: WHAT IS THE RIGHT BALANCE?
Moderator: Valerie S. L. Williams PhD, Senior Director, Patient-Reported Outcomes, RTI Health Solutions,
Research Triangle Park, NC, USA
Panelists: Carla DeMuro-Mercon MS, Senior Director, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA; Bryce Reeve PhD, Program Director and Psychometrician, National Cancer Institute, Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences, Bethesda, MD, USA; M. Haim Erder PhD, Vice President, Forest Research Institute, Health Economics & Outcomes, Jersey City, NJ, USA |
| |
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES |
| 2:45PM-3:45PM |
IP9: DEVELOPING AND ADDRESSING PAYER EVIDENCE REQUIREMENTS FOR MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE: HOW CAN HEALTH OUTCOMES AND ECONOMICS APPROACHES HELP FILL THE GAP?
Moderator: Eric C. Faulkner MPH, Senior Director, RTI Health Solutions, Pricing & Reimbursement, Research Triangle Park, NC, USA
Panelists: Patricia Deverka MD, MS, MPE, Research Associate Professor, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; David L. Veenstra PharmD, PhD, Associate Professor, Department of Pharmacy, University of Washington, Seattle, WA, USA; Penny Mohr MA, Vice President, Programs, Center for Medical Technology Policy, Baltimore, MD, USA |
| |
|
| 2:45PM-3:45PM |
IP10: HTA IN THE AGE OF OBAMA
Moderator: Peter J. Neumann ScD, Director, Tufts Medical Center, Center for the Evaluation of Value and Risk in Health, Boston, MA, USA
Panelists: Peter Bach MD, MAAP, Associate Attending Physician, Memorial Sloan-Kettering Cancer Center, Former Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, New York, NY, USA; Brian Sweet BSPharm, MBA, Chief Pharmacy Officer, WellPoint, Indianapolis, IN, USA; Jeff Thompson MD, MPH, Chief Medical Officer, Washington State Department of Social & Health Services, Health and Recovery Services Administration, Olympia, WA, USA. |
| 3:45PM-4:00PM |
|
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II |
| |
| 4:00PM-5:00PM |
|
WORKSHOPS – SESSION II |
| |
|
CLINICAL OUTCOMES RESEARCH |
| 4:00PM-5:00PM |
W8:
COMPARATIVE EFFECTIVENESS WITHOUT HEAD-TO-HEAD TRIALS: INDIRECT COMPARISONS USING PRIMARY AND PUBLISHED CLINICAL TRIAL DATA
Discussion Leaders: James Signorovitch PhD, Associate, Analysis Group, Inc, Boston, MA, USA; Andrew P. Yu PhD, Manager, Analysis Group, Inc, Boston, MA, USA; Eric Wu PhD, Vice President, Analysis Group, Inc, Boston, MA, USA |
| |
|
| 4:00PM-5:00PM |
W9: ANALYSIS OF EFFECTIVENESS AND COST-EFFECTIVENESS IN PATIENT REGISTRIES
Discussion Leaders: Maria Malmenäs MSc, Manager Biostatistics, Outcome Surveys, Shire Human Genetic Therapies, Global Medical Affairs, Danderyd, Sweden; Margaret Hux MSc, Lead Analyst, i3 Innovus, Burlington, ON, Canada; Mike Novotny MBA, MA, CEO, Medrio, San Francisco, CA, USA; Lusine Abrahamyan MD, MPH, PhD(c), Graduate Student, University of Toronto, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada |
| |
ECONOMIC OUTCOMES RESEARCH |
| 4:00PM-5:00PM |
W10: UNCERTAINTY AROUND AN EFFICIENCY FRONTIER
Discussion Leaders: J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President Health Economics, United BioSource Corporation, Health Care Analytics, Lexington, MA, USA; Isao Kamae MD, DrPH, Professor, Keio University Graduate School of Health Management, Graduate School of Health Management, Fujisawa, Kanagawa, Japan; Charalabos-Markos Dintsios MA, MPH, Research Fellow, Institute for Quality and Efficiency in Health Care (IQWiG), Pharmaceutical Products Evaluation, Cologne, Germany |
| |
PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH |
| 4:00PM-5:00PM |
W11: STILL WRESTLING WITH SPECIFYING THE CONCEPTUAL FRAMEWORK OF A PRO INSTRUMENT? TWO TOOLS TO HELP YOU PIN IT DOWN: THE PRO CONCEPT TAXONOMY AND THE PRO INSTRUMENT HIERARCHY
Discussion Leaders: Pennifer Erickson PhD, Co-founder, OLGA, State College, PA, USA; Richard J. Willke PhD, Senior Director/Group Leader, Pfizer, Outcomes Research, Peapack, NJ, USA |
| |
USE OF REAL WORLD DATA |
| 4:00PM-5:00PM |
W12: A TAXONOMY FOR THE DESIGN, DEVELOPMENT AND IMPLEMENTATION OF PATIENT REGISTRIES
Discussion Leaders: Eric K. Gemmen MA, Senior Director, Medical Affairs, Epidemiology & Outcomes Research, Quintiles, Inc, Late Phase & Safety Services, Falls Church, VA, USA; Claudio Faria PharmD, MPH, Associate Director of Clincal Research, University of Massachusetts Medical School, Boston, MA, USA |
| |
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH |
| 4:00PM-5:00PM |
W13: FROM EVIDENCE TO ACCESS: A MORE TRANSPARENT FORMULARY DECISION-MAKING PROCESS
Discussion Leaders: Robert Dubois MD, PhD, Chief Medical Officer, Cerner LifeSciences, Beverly Hills, CA, USA; Sean D. Sullivan PhD, RPh, Professor of Pharmacy and Public Health and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA; Mark Helfand MD, MPH, Director, Oregon Evidence-based Practice Center, Professor of Medicine and Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA; Barbara McNeil MD, PhD, Ridley Watts Professor and Head of Department, Harvard Medical School, Department of Health Care Policy, Boston, MA, USA |
| |
|
| 4:00PM-5:00PM |
W14: VALUE BASE PRICING, WHAT IS IT AND IS IT RELEVANT FOR THE US?
Discussion Leaders: Alistair McGuire PhD, Chair in Health Economics, LSE Health and Social Care, London, UK; Monique Martin MSc, MBA, Vice-President UK Operations, i3 Innovus, Uxbridge, Middlesex, UK; Stephen Clark BA, Vice President, Market Access and Reimbursement, i3 Innovus, Eden Prairie, MN, USA |
| 5:15PM-6:00PM |
|
ISPOR FORUMS (6 concurrent session) |
5:15PM-6:00PM |
|
Quality Improvement In Cost Effectiveness Research
Recommendations on facilitating the improvement of health economic research and its use in impacting health care decisions will be presented. This session will focus on a review and analysis of global economic guidelines, statistical problems in cost effectiveness analyses and models, scope of quality guidelines in journals and publications, and overcoming barriers to the use of cost effectiveness data by decision-makers. This forum provides an opportunity to comment on the draft ISPOR Task Force Report: Quality Improvement of Cost Effectiveness Research.
Presented by the ISPOR Quality Improvement of Cost Effectiveness Research Task Force
Moderator: William McGhan PharmD, PhD, Chair, ISPOR Quality Improvement of Cost Effectiveness Research Task Force, Professor of Pharmacy and Health Policy, University of the Sciences, Philadelphia, PA, USA
Speakers: Maiwenn Al PhD, Senior Research Fellow, institute for Medical Technology Assessment (iMTA), Erasmus MC, Rotterdam, The Netherlands; Jalpa A. Doshi PhD, Research Assistant Professor of Medicine, General Internal Medicine; Director, Economic Evaluations Unit, Center for Evidence-Based Practice; Director, Value-Based Insurance Design Initiatives, Center for Health Incentives University of Pennsylvania, Philadelphia, PA, USA; Isao Kamae MD, DrPH, Professor of Applied Medical Statistics and Decision Sciences, Kobe University, Kobe, Japan; Steven E. Marx PharmD, MS, Associate Director, Global Pharmaceutical Research & Development, Abbott Laboratories, Chicago, IL, USA; Donna Rindress PhD, President & Managing Director, BioMedCom Consultants, Inc., Montreal, QC, Canada |
5:15PM-6:00PM |
Reliability & Validity of Data Sources for Health & Disease Management: Rationality in an Era of Controversy
This forum will present a summary of a new book: Reliability and Validity of Data Sources for Health and Disease Management. The ISPOR Health & Disease Management Special Interest Group (SIG) has completed the first draft of this handbook for health and disease management practitioners, payers, and researchers. It provides a comprehensive overview of the available U.S. and international data sources, including an assessment of their reliability and validity, methods used to examine these data, and approaches for experimental and retrospective research designs.
Presented by the ISPOR Health & Disease Management Special Interest Group
Moderator: Elizabeth Molsen RN, ISPOR, Lawrenceville, NJ, USA;
Speakers: Renée J. Goldberg Arnold PharmD, RPh, Adjunct Associate Professor, Community and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Carla Zema PhD, Assistant Professor, Alex G. McKenna School of Business, Economics and Government, St. Vincent College, Latrobe, PA, USA; Robin Turpin PhD, Senior Director, Global Health Economics, Baxter Healthcare, Deerfield, IL, USA; Christopher R. Frei Pharm D, MSc, Assistant Professor, University of Texas, Austin, TX, USA; Kristen Migliaccio-Walle BS, United BioSource Corporation, Lexington, MA, USA; Joel Hay PhD, Professor, University of Southern California, Los Angeles, CA, USA; Oliver Mast MSc, Head, Global Reimbursement Diabetes Care, Roche Diagnostics, Mannheim, Germany; Dominick Esposito DrPH, BA, Senior Economist, Mathematica Policy Research, Princeton, NJ, USA
|
|
|
5:15PM-6:00PM |
Reimbursement Policy Decision making process in the US: Private versus Public.
The differences of two USA Health care systems, one public based (VA) and the other private based (Premera Blue Cross) focusing on coverage and reimbursement systems from the payers’ and providers’ perspective will be debated .
Presented by the ISPOR HTA Council & Special Interest Group
Moderator: Karl Matuszewski MS, PharmD, Vice President, Editor-in-Chief Elsevier / Gold Standard, Tampa, FL;
Speakers: Elizabeth Adams RRT, MPH, Research Analyst, VA Technology Assessment Program, Office of Patient Care Services, Boston, MA, USA; John Watkins RPh, MPH, Pharmacy Manager, Formulary Development, Premera Blue Cross, Bothell, Washington, USA
|
5:15PM-6:00PM |
Patient Registry Design, Operations, Data Analysis, Reporting & Publishing: Putting All the Pieces Together
Discussion will open with classification, characteristics, design, implementation, and operation of registries and conclude with the analysis, use and publication of registry data.
Presented by the ISPOR Patient Registry Special Interest Group
Moderator: Leanne Larson MHA, Vice President, Sg2 Healthcare Intelligence, Skokie, IL, USA;
Speakers: Chris L. Pashos PhD, Vice President, HERQuLES, Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA; Eric Gemmen MA, Senior Director, Medical Affairs, Epidemiology & Outcomes Research, Quintiles Late Phase & Safety Services, Falls Church, VA, USA; Chris Blanchette PhD, MS, MA, Director, Lovelace Respiratory Research Institute, Davidson, NC, USA; Shital Kamble MS, PhD(c); Research Assistant, University of North Carolina, Charlotte, NC, USA; Diana Frame MS, Consultant, Frame Research, Brooklyn, NY, USA; Leanne Larson MHA, Vice President, Sg2 Healthcare Intelligence, Skokie, IL, USA; Mike Novotny MBA, MA, CEO, Medrio, San Francisco, CA, USA, Maria Malmenäs MSc, Manager Biostatistics, Outcome Surveys, Global Medical Affairs, Shire Human Genetic Therapies, Danderyd, Sweden ; Marg Hux PhD, Associate Director, Health Economics & Outcomes, i3Innovus, Burlington, ON, Canada |
5:15PM-6:00PM |
Assessment, Determinants & Economics of Medication Compliance & Persistence
Methodology used for conducting trials in medication compliance /persistence research will be presented. The economic implications of non-compliance will be examined as well as a discussion on key determinants of non-compliance.
Presented by the ISPOR Medication Compliance & Persistence Special Interest Group
Moderator: Dyfrig Hughes PhD, MRPharmS, Deputy Director, Centre for Economics and Policy in Health, IMSCaR, Bangor University, Bangor, Wales LL57 1UT
Speakers: Femida Gwadry-Sridhar BScPhm, MSc, PhD, Assistant Professor, University of Western Ontario, Department of Medicine, London, ON, Canada; Elizabeth Manias MPharm, PhD, Professor, Associate Head of Research, The University of Melbourne, School of Nursing and Social Work, Carlton, Australia; Judith A. Shinogle MSc, PhD, Senior Research Associate, University of Maryland, Maryland Institute for Policy Analysis and Research, Baltimore, MD, USA |
5:15PM-6:00PM |
Risk Benefit Management
Key issues for determining metrics and methodologies to quantify risks and benefits will be discussed. In addition, an overview of worldwide risk benefit monitoring with specific comparisons between EMEA and US guidelines will be presented.
Presented by members of the ISPOR Risk Management Special Interest Group
Moderator: Dennis W. Raisch, PhD, MS, RPh, Professor, PEPPOR (Pharmacoeconomics, Epidemiology, Public Policy and Outcomes Research), College of Pharmacy, University of New Mexico, Albuquerque, NM, USA
Speakers: Dennis W. Raisch, PhD, MS, RPh, Professor, PEPPOR (Pharmacoeconomics, Epidemiology, Public Policy and Outcomes Research), College of Pharmacy, University of New Mexico, Albuquerque, NM, USA; Jayashri Sankaranarayanan MPharm, PhD, Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA; Jeff J. Guo, PhD, Associate Professor of Pharmacoepidemiology and Pharmacoeconomics, University of Cincinnati, College of Pharmacy, Cincinnati, OH, USA; John Doyle DrPH, Managing Director and Practice Leader, Market Access, Quintiles Global Consulting, Hawthorne, NY, USA & Adjunct Assistant Professor, Departments of Epidemiology and Healthcare Policy & Management, Mailman School of Public Health, Columbia University, New York, NY, USA |
5:15PM-6:00PM |
Update on Comparative Effectiveness and Health Information Technology Legislation and Policy Developments, and Their Impact on Pharmacoeconomics
This forum will provide information on the recently passed American Recovery and Reinvestment Act (ARRA) and a discussion of proposed health reform legislation and their research implications for ISPOR members. The objectives for this program include a review of developments in comparative effectiveness and health information technology legislation and their relationship to pharmacoeconomic research; discussion of proposed health reform legislation and the roles comparative effectiveness and electronic health records will play; and a discussion of the implications of the growth of government investment in comparative effectiveness and health information technology on the future of pharmacoeconomics and ISPOR.
Presented by the ISPOR Health Science Policy Council
Moderator: Jean Paul Gagnon PhD, RPh, Senior Director, Public Policy, Aventis Pharmaceuticals Inc, Bridgewater, NJ, USA
Speakers: Bryan R. Luce, PhD, MBA, Chair, ISPOR Health Science Policy Council & Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA; Jean Paul Gagnon PhD, RPh, Senior Director, Public Policy, Aventis Pharmaceuticals Inc, Bridgewater, NJ, USA; Joel Hay PhD, Professor, USC Department of Pharmaceutical Economics & Policy, Los Angeles, CA, USA |
| 6:00PM-7:00PM |
|
ISPOR FORUM |
6:00PM-7:00PM |
|
Drug Provisions for the Population of the Russian Federation
Presented in Russian with English slides and handout
A report from the Formulary Committee of the Russian Academy of Medical Sciences on the challenges of determining and obtaining drug treatments for the general population will be presented
Presented by the ISPOR Russia Chapter
Moderator: Professor Pavel Vorobyev MD, PhD Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President ISPOR Russia Chapter
Speakers: Professor Pavel Vorobyev MD, PhD Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President ISPOR Russia Chapter; Oleg Borisenko MD, Executive Director, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia |
| |
| 6:00PM-7:00PM |
|
POSTER AUTHOR DISCUSSION HOUR – SESSION II |
| |
|
|
| 6:00PM-7:30PM |
|
EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II |
| |
|
|
| 7:30PM-11:00PM |
|
ISPOR SOCIAL EVENT - TROPICAL FLORIDA NIGHT FEATURING THE ISPOR MONTE CARLOS |
| |
|
(Separate Registration Required - REGISTER NOW) |
|
|
